Breaking News Instant updates and real-time market news.

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:47
10/21/18
10/21
12:47
10/21/18
12:47

Dynavax's SD-101, Keytruda combo still shows 70% ORR in Advanced Melanoma

Dynavax (DVAX) presented interim data from its ongoing Phase 1b/2 SYNERGY-001 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with Keytruda, an anti-PD-1 therapy developed by Merck (MRK) in patients with advanced melanoma naive to anti-PD-1/L1 therapy. The company reported results on a total of 87 patients comparing two different doses of SD-101. In the study, 47 patients received less than or equal to 2mg of SD-101 in 1-4 lesions and 40 patients received 8 mg in a single lesion. The primary endpoints of this dose-expansion/dose-finding study are safety and preliminary efficacy. The results showed a 70% overall response rate in advanced melanoma patients naive to anti-PD-1/L1 therapy who received the less than or equal to 2 mg dose of SD-101 and a 48% ORR in the group receiving the 8 mg dose of SD-101. The combination of SD-101 and Keytruda remains well tolerated with adverse events related to SD-101 being transient, mild to moderate flu-like symptoms.

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

MRK

Merck

$72.34

0.12 (0.17%)

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

DVAX Dynavax
$10.90

-0.47 (-4.13%)

05/10/18
JPMS
05/10/18
UPGRADE
Target $27
JPMS
Overweight
Dynavax upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Dynavax Technologies to Overweight and raised his price target for the shares to $27 from $25 following the company's Q1 results. The analyst believes TLR9 agonist SD-101 is an underappreciated asset.
05/10/18
JPMS
05/10/18
UPGRADE
Target $27
JPMS
Overweight
JPMorgan upgrades Dynavax on 'vastly underappreciated' SD-101
JPMorgan analyst Anupam Rama upgraded Dynavax Technologies to Overweight from Neutral and raised his price target for the shares to $27 from $25. While a Heplisav launch inflection in 2019 is widely expected, the company's SD-101 opportunity is being "vastly underappreciated" at current share levels, Rama tells investors in a research note. SD-101 has shown encouraging early signals of efficacy in both the melanoma and head and neck indications, the analyst contends. Rama points out that a Phase 2 melanoma update is expected next month at ASCO. He likes the stocks' reward/risk profile going into the readout. The analyst sees 30%-60% upside potential versus 0%-10% downside risk on the data.
05/17/18
JPMS
05/17/18
NO CHANGE
JPMS
Overweight
Dynavax should trade to $21-$22 on abstract data, says JPMorgan
JPMorgan analyst Anupam Rama believes shares of Dynavax should trade up 5%-15% to the $21-$22 range on the SD-101 melanoma ASCO abstract. While some on the Street were inappropriately setting the benchmark at 70%-80% overall response, the abstract data "very much put the early efficacy signals" of SD-101 plus pembrolizumab in the ballpark of nivolumab plus ipilimumab from CHECKMATE-067, with a cleaner safety profile, Rama tells investors in a research note. He says the abstract met his "base case / win / upside scenario."
08/07/18
CANT
08/07/18
NO CHANGE
Target $30
CANT
Overweight
Dynavax price target raised to $30 from $27 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Dynavax Technologies to $30 and reiterates an Overweight rating on the shares following the company's Q2 results. The analyst believes there are a "number of opportunities in the near future for Dynavax that could lead to upside for the company," including future Heplisav-B vaccine sales and a Phase 3 trial initiation for SD-101 in advanced melanoma.
MRK Merck
$72.34

0.12 (0.17%)

10/11/18
FBCO
10/11/18
NO CHANGE
Target $81
FBCO
Outperform
Merck price target raised to $81 from $71 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for Merck to $81 from $71, while reiterating an Outperform rating on the shares. While the shares have had a significant move this year, the analyst sees room for additional upside as the company continues to roll out Keytruda, most notably in the 1st line non-small cell lung setting. However, Divan also acknowledges longer-term investors remain concerned about how the company will navigate the Januvia patent expiration in mid-2022.
10/16/18
BTIG
10/16/18
INITIATION
Target $82
BTIG
Buy
Esperion initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated Esperion (ESPR) with a Buy rating and a price target of $82, saying that with its development of bempedoic acid, or BA, to reduce cholesterol, the next key question is about the drug's safety. The analyst notes that while the data from Study 1 in May were disappointing, Study 2 readout in the next few weeks should have more answers. Shrader adds that the introduction of "non-stain" into the cholesterol market has already worked for Merck's (MRK) Zetia, and if BA is perceived well on its safety profile, it is "highly supportive" of its investment story.
10/16/18
SBSH
10/16/18
NO CHANGE
Target $79
SBSH
Buy
Merck price target raised to $79 from $70 at Citi
Citi analyst Andrew Baum raised his price target for Merck (MRK) to $79 and reiterates a Buy rating on the shares. Following upward revisions to his Lynparza expectations, the analyst raised his earnings forecasts for Merck by 1%-9% over the 2021 to 2025 timeframe. The analyst anticipates that positive Lynparza first-line ovarian cancer trial will make Lynparza standard of care in wild type first-line ovarian cancer patients and leaving it well positioned to take market share in immuno-oncology based combinations post 2021. Baum also raised his price target for AstraZeneca (AZN), Merck's partner on Lynparza, to GBP 70 from GBP 62. He also has a Buy rating on those shares.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

RIO

Rio Tinto

$57.03

1.04 (1.86%)

13:49
03/18/19
03/18
13:49
03/18/19
13:49
Periodicals
SEC can pursue Rio Tinto fraud cause, judge says, Reuters reports »

U.S. District Judge…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CREE

Cree

$56.77

-0.14 (-0.25%)

13:45
03/18/19
03/18
13:45
03/18/19
13:45
Options
Cree call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

ON

ON Semiconductor

$21.95

-0.23 (-1.04%)

13:39
03/18/19
03/18
13:39
03/18/19
13:39
Hot Stocks
ON Semiconductor has introduced two new silicon carbide, SiC Mosfet devices »

ON Semiconductor has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,180.85

-4.41 (-0.37%)

, GOOGL

Alphabet Class A

$1,184.84

-6.94 (-0.58%)

13:38
03/18/19
03/18
13:38
03/18/19
13:38
Periodicals
Google denies working with Chinese military, NBCNews reports »

Google denied…

GOOG

Alphabet

$1,180.85

-4.41 (-0.37%)

GOOGL

Alphabet Class A

$1,184.84

-6.94 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 27

    Mar

  • 04

    Apr

  • 27

    Oct

13:35
03/18/19
03/18
13:35
03/18/19
13:35
General news
U.S. corporate bond update: a couple of issuers are jumping in »

U.S. corporate bond…

CCI

Crown Castle

$124.05

-1.03 (-0.82%)

13:35
03/18/19
03/18
13:35
03/18/19
13:35
Options
Crown Castle put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
03/18/19
03/18
13:35
03/18/19
13:35
General news
Treasury Option Action: call spread liquidation »

Treasury Option Action:…

FB

Facebook

$159.31

-6.68 (-4.02%)

13:33
03/18/19
03/18
13:33
03/18/19
13:33
Periodicals
Blumenthal wants Facebook probe after live stream of mosque attack, NY Post says »

Senator Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

13:30
03/18/19
03/18
13:30
03/18/19
13:30
Periodicals
U.K. speaker says parliament won't vote again on Brexit deal, WSJ reports »

John Bercow, speaker of…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$281.92

0.61 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNL

Global Net Lease

$18.38

-0.1 (-0.54%)

13:29
03/18/19
03/18
13:29
03/18/19
13:29
Conference/Events
Global Net Lease management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 27

    Mar

  • 28

    Mar

  • 15

    Apr

NVRO

Nevro

$44.31

0.56 (1.28%)

13:27
03/18/19
03/18
13:27
03/18/19
13:27
Conference/Events
Nevro management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

NVRO

Nevro

$44.15

0.4 (0.91%)

13:27
03/18/19
03/18
13:27
03/18/19
13:27
Conference/Events
Nevro management to meet with SVB Leerink »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

APYX

Apyx Medical

$7.93

0.005 (0.06%)

13:25
03/18/19
03/18
13:25
03/18/19
13:25
Conference/Events
Apyx Medical management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

T

AT&T

$30.77

0.09 (0.29%)

13:24
03/18/19
03/18
13:24
03/18/19
13:24
Periodicals
Kevin Tsujihara ousted as Warner Bros. CEO, CNBC reports »

Kevin Tsujihara has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 24

    Apr

  • 26

    Apr

  • 20

    May

CXP

Columbia Property

$21.99

-0.13 (-0.59%)

13:21
03/18/19
03/18
13:21
03/18/19
13:21
Conference/Events
Columbia Property management to meet with JMP Securities »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

BSX

Boston Scientific

$37.77

-2.38 (-5.93%)

13:20
03/18/19
03/18
13:20
03/18/19
13:20
Options
Quarter million dollar block of calls sold to open in Boston Scientific »

Quarter million dollar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

  • 28

    May

MIK

Michaels

$11.72

0.04 (0.34%)

, DSW

DSW

$25.05

-0.34 (-1.34%)

13:19
03/18/19
03/18
13:19
03/18/19
13:19
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MIK

Michaels

$11.72

0.04 (0.34%)

DSW

DSW

$25.05

-0.34 (-1.34%)

HDS

HD Supply

$42.88

-0.12 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

REGN

Regeneron

$408.15

-6.03 (-1.46%)

, DERM

Dermira

$12.46

5.63 (82.43%)

13:17
03/18/19
03/18
13:17
03/18/19
13:17
On The Fly
Dermira rises, Regeneron slips on eczema treatment study results »

Shares of Dermira (DERM)…

REGN

Regeneron

$408.15

-6.03 (-1.46%)

DERM

Dermira

$12.46

5.63 (82.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
03/18/19
03/18
13:17
03/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
03/18/19
03/18
13:16
03/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBCP

Home Bancorp

$36.50

0.59 (1.64%)

13:14
03/18/19
03/18
13:14
03/18/19
13:14
Hot Stocks
Home Bancorp CEO John Bordelon sells over $232K shares of company stock »

Home Bancorp CEO John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$31.38

0.69 (2.25%)

13:14
03/18/19
03/18
13:14
03/18/19
13:14
Periodicals
Elanco tells Bloomberg CEO not planing to sell shares at lockup »

Elanco CEO Jeffrey…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

APEN

Apollo Endosurgery

$3.29

-0.06 (-1.79%)

13:13
03/18/19
03/18
13:13
03/18/19
13:13
Recommendations
Apollo Endosurgery analyst commentary  »

Piper says Apollo's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 18

    May

  • 28

    May

QQQ

Invesco QQQ Trust

$178.07

0.1542 (0.09%)

13:10
03/18/19
03/18
13:10
03/18/19
13:10
Options
50K Invesco QQQ Jun 188 - 192 call spreads sold at 95c »

50K Invesco QQQ Jun 188 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARS

Cars.com

$22.75

0.04 (0.18%)

13:05
03/18/19
03/18
13:05
03/18/19
13:05
Options
Cars.com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.